Winichakoon Poramed, Chanloung Wanitcha, Nantsupawat Teerapat, Louthrenoo Worawit
Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Vaccines (Basel). 2022 Jun 26;10(7):1022. doi: 10.3390/vaccines10071022.
Adult-onset Still's disease (AOSD)-like syndrome has rarely been reported as a complication of COVID-19 vaccination. This study reports a 31-year-old female patient who presented with fever, myalgia, arthralgia, pleuropericarditis, leukocytosis, and transaminitis following ChAdOx1 vaccination, and met Yamaguchi's criteria. A PubMed literature search, performed up until March 2022, identified 10 such cases. A total of 11 cases, including the one in this report, developed AOSD-like syndrome after administration of the viral vector (ChAdOx1) vaccine (six patients) and mRNA vaccine (five patients: BNT162b2 in four and mRNA-1273 in one). There were four male and seven female patients, with their median (Q1, Q3) age and the onset of symptoms after vaccination being 36 years (29, 45) and 10 days (6, 13), respectively. Fever (100%), arthralgia/arthritis (90.9%), skin rashes (81.8%), and sore throat (81.8%) were the main clinical findings. Pericarditis (45.5%), myocarditis/cardiac dysfunction (36.4%), pleuritis (54.6%), and pulmonary infiltrations (36.4%) were also common. One patient developed macrophage activation syndrome. One patient responded well to non-steroidal anti-inflammatory drugs, and the other six showed a good response to high-dose corticosteroids alone. Of the remaining four patients, who showed partial responses to high dose corticosteroids, showed good responses to biological agents. AOSD-like syndrome following COVID-19 vaccination shared many similar clinical features and treatment outcomes to those of idiopathic AOSD (but with a higher prevalence of cardiopulmonary involvement in the former). Physicians should be aware of this extremely rare complication to achieve early diagnosis and provide proper management.
成人斯蒂尔病(AOSD)样综合征作为新冠病毒疫苗接种的并发症鲜有报道。本研究报告了一名31岁女性患者,其在接种ChAdOx1疫苗后出现发热、肌痛、关节痛、胸膜心包炎、白细胞增多和转氨酶升高,并符合山口标准。截至2022年3月进行的PubMed文献检索,共识别出10例此类病例。包括本报告中的病例在内,共有11例在接种病毒载体(ChAdOx1)疫苗(6例患者)和mRNA疫苗(5例患者:4例接种BNT162b2,1例接种mRNA-1273)后发生AOSD样综合征。患者中男性4例,女性7例,年龄中位数(四分位间距)为36岁(29,45),接种疫苗后症状出现时间中位数为10天(6,13)。主要临床表现为发热(100%)、关节痛/关节炎(90.9%)、皮疹(81.8%)和咽痛(81.8%)。心包炎(45.5%)、心肌炎/心脏功能障碍(36.4%)、胸膜炎(54.6%)和肺部浸润(36.4%)也很常见。1例患者发生巨噬细胞活化综合征。1例患者对非甾体抗炎药反应良好,另外6例仅对大剂量皮质类固醇反应良好。其余4例对大剂量皮质类固醇部分反应的患者,对生物制剂反应良好。新冠病毒疫苗接种后发生的AOSD样综合征与特发性AOSD有许多相似的临床特征和治疗结果(但前者心肺受累的患病率更高)。医生应意识到这种极其罕见的并发症,以便早期诊断并提供适当的治疗。